ABBOTT INDIA LIMITED

🇮🇳India

Country: 🇮🇳India

Ownership: Private

Established: 1888-01-01

Employees: 73K

Market Cap: $7.5B

Website: http://www.abbott.com

Clinical Trials

A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333

Phase 1

Completed

Conditions: HCV Infection

Interventions: Drug: ABT-333
Drug: ketoconazole
Drug: placebo

First Posted Date: 2008-10-08

Last Posted Date: 2010-10-13

Lead Sponsor: Abbott

Target Recruit Count: 45

Registration Number: NCT00768690

Locations: 🇺🇸
Site Reference ID/Investigator# 12701, Waukegan, Illinois, United States

Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira

Phase 4

Terminated

Conditions: Rheumatoid Arthritis

Interventions: Drug: Humira (adalimumab)

First Posted Date: 2008-09-29

Last Posted Date: 2009-11-19

Lead Sponsor: Abbott

Target Recruit Count: 14

Registration Number: NCT00761514

Locations: 🇵🇷
San Juan Arthritis & Research Center, San Juan, Puerto Rico
🇵🇷
AJP Med, Inc. PSA, Caguas, Puerto Rico

Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors

Phase 1

Withdrawn

Conditions: Solid Tumors

Interventions: Drug: ABT-869
Drug: Tarceva

First Posted Date: 2008-09-17

Last Posted Date: 2011-01-19

Lead Sponsor: Abbott

Registration Number: NCT00754104

A Study of ABT-072 in Healthy and Hepatitis C Virus Genotype 1-Infected Adults

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: ABT-072
Drug: placebo

First Posted Date: 2008-09-15

Last Posted Date: 2010-10-21

Lead Sponsor: Abbott

Target Recruit Count: 100

Registration Number: NCT00752687

Locations: 🇺🇸
Global Medical Information, Abbott Park, Illinois, United States

Assess the Oral Bioavailability of New ABT-263 Formulations

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia
Lymphomas
Leukemias

Interventions: Drug: ABT-263

First Posted Date: 2008-08-28

Last Posted Date: 2010-10-07

Lead Sponsor: Abbott

Target Recruit Count: 36

Registration Number: NCT00743028

Locations: 🇺🇸
Site Reference ID/Investigator# 16341, Bethesda, Maryland, United States
🇺🇸
Site Reference ID/Investigator# 10282, Santa Monica, California, United States
🇺🇸
Site Reference ID/Investigator# 10281, Encinitas, California, United States

and more 2 locations

A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects

Phase 1

Terminated

Conditions: HIV
Tuberculosis

Interventions: Drug: lopinavir/ritonavir
Drug: rifabutin

First Posted Date: 2008-08-28

Last Posted Date: 2010-11-02

Lead Sponsor: Abbott

Target Recruit Count: 15

Registration Number: NCT00743470

Locations: 🇺🇸
Site Reference ID/Investigator# 11441, Waukegan, Illinois, United States

A Trial of PDL192 in Subjects With Advanced Solid Tumors

Phase 1

Completed

Conditions: Cancer

Interventions: Biological: PDL192

First Posted Date: 2008-08-20

Last Posted Date: 2012-01-06

Lead Sponsor: Abbott

Target Recruit Count: 30

Registration Number: NCT00738764

Locations: 🇺🇸
Site Reference ID/Investigator# 53365, Scottsdale, Arizona, United States
🇺🇸
Site Reference ID/Investigator# 53364, Aurora, Colorado, United States

Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet

Phase 4

Completed

Conditions: Psoriasis

Interventions: Biological: Placebo
Biological: Adalimumab

First Posted Date: 2008-08-15

Last Posted Date: 2010-11-01

Lead Sponsor: Abbott

Target Recruit Count: 81

Registration Number: NCT00735787

Locations: 🇺🇸
Site Reference ID/Investigator# 10173, Dallas, Texas, United States
🇨🇦
Site Reference ID/Investigator# 10175, Waterloo, Ontario, Canada
🇺🇸
Site Reference ID/Investigator# 10005, Bakersfield, California, United States

and more 14 locations

A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Elotuzumab (HuLuc63)

First Posted Date: 2008-08-01

Last Posted Date: 2012-08-23

Lead Sponsor: Abbott

Target Recruit Count: 28

Registration Number: NCT00726869

Locations: 🇺🇸
Site Reference ID/Investigator# 63853, Los Angeles, California, United States
🇺🇸
Site Reference ID/Investigator# 63850, Buffalo, New York, United States
🇺🇸
Site Reference ID/Investigator# 63855, Chicago, Illinois, United States

and more 5 locations

Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)

Phase 3

Completed

Conditions: Human Immunodeficiency Virus Infection

Interventions: Drug: lopinavir/ritonavir (LPV/r)
Drug: raltegravir (RAL)
Drug: emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)

First Posted Date: 2008-07-08

Last Posted Date: 2012-02-14

Lead Sponsor: Abbott

Target Recruit Count: 206

Registration Number: NCT00711009

Locations: 🇺🇸
Site Reference ID/Investigator# 8433, Houston, Texas, United States
🇺🇸
Site Reference ID/Investigator# 8395, Atlanta, Georgia, United States
🇨🇦
Site Reference ID/Investigator# 7831, Toronto, Ontario, Canada

and more 34 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy